GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Clever Leaves Holdings Inc (NAS:CLVR) » Definitions » Capex-to-Operating-Cash-Flow

Clever Leaves Holdings (Clever Leaves Holdings) Capex-to-Operating-Cash-Flow : 0.00 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Clever Leaves Holdings Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Clever Leaves Holdings's Capital Expenditure for the three months ended in Dec. 2023 was $0.16 Mil. Its Cash Flow from Operations for the three months ended in Dec. 2023 was $-1.54 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Clever Leaves Holdings Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Clever Leaves Holdings's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clever Leaves Holdings Capex-to-Operating-Cash-Flow Chart

Clever Leaves Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
- - - - -

Clever Leaves Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Clever Leaves Holdings's Capex-to-Operating-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Clever Leaves Holdings's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clever Leaves Holdings's Capex-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Clever Leaves Holdings's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Clever Leaves Holdings's Capex-to-Operating-Cash-Flow falls into.



Clever Leaves Holdings Capex-to-Operating-Cash-Flow Calculation

Clever Leaves Holdings's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.031) / -11.508
=N/A

Clever Leaves Holdings's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0.156) / -1.543
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clever Leaves Holdings  (NAS:CLVR) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Clever Leaves Holdings Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Clever Leaves Holdings's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Clever Leaves Holdings (Clever Leaves Holdings) Business Description

Traded in Other Exchanges
N/A
Address
19-B Parque Industrial Tibitoc, Tocancipá, Cundinamarca, Bodega, Colombia, BC, CAN
Clever Leaves Holdings Inc is a producer of pharmaceutical and consumer cannabis brands. The company operates and has investments in Canada, Colombia, Germany, Portugal, and the United States. The company operates in two reportable segments, 1. The Cannabinoid operating segment: is comprised of the Company's cultivation, extraction, and commercialization of cannabinoid products. 2. Non-Cannabinoid operating segment is engaged in the business of formulating, manufacturing, marketing, selling, distributing, and otherwise commercializing nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements.
Executives
Andres Fajardo director, officer: President CLEVER LEAVES HOLDINGS INC., 489 FIFTH AVENUE, 27TH FLOOR, NEW YORK NY 10017
Julian Wilches officer: Chief Regulatory Officer CLEVER LEAVES HOLDINGS INC., 489 FIFTH AVENUE, 27TH FLOOR, NEW YORK NY 10017
Hague Henry R Iii officer: Chief Financial Officer 489 FIFTH AVENUE, 27TH FLOOR, NEW YORK NY 10017
Gary M Julien director ONE LANDMARK SQUARE, 22ND FLOOR, STAMFORD CT 06901
William Muecke director C/O CLEVER LEAVES HOLDINGS, 6501 CONGRESS AVE, SUITE 240, BOCA RATON FL 33487
David Kastin officer: General Counsel C/O VITAMIN SHOPPE, INC., SECAUCUS NJ 07094
Kyle Detwiler director, officer: Chief Executive Officer CLEVER LEAVES HOLDINGS INC., 489 FIFTH AVENUE, 27TH FLOOR, NEW YORK NY 10017
George J Schultze 10 percent owner C/O SCHULTZE ASSET MANAGEMENT, LLC, 3000 WESTCHESTER AVENUE, PURCHASE NY 10577
Elisabeth H Demarse director CREDITCARDS.COM, 13809 RESEARCH BOULEVARD, SUITE 906, AUSTIN TX 78750
Etienne H. Deffarges director ACCRETIVE HEALTH, INC., 401 NORTH MICHIGAN AVENUE, SUITE 2700, CHICAGO IL 60611
Schultze Special Purpose Acquisition Sponsor, Llc 10 percent owner 800 WESTCHESTER AVENUE, SUITE 632, RYE BROOK NY 10573
Amit Pandey officer: Interim CFO CLEVER LEAVES HOLDINGS INC., 489 FIFTH AVENUE, 27TH FLOOR, NEW YORK NY 10017